![](https://www.Immune-System-Research.com/"wp-content/uploads"/2021/06/BRD9876-is-an-ATP-non-competitive-and-Mitotic-Kinesin-5-Eg5-Inhibitor-2021-06-05.jpg)
Multiple myeloma cells have greater phosphorylated Eg5 than hematopoietic cells. Eg5 phosphorylation increases microtubule binding and uniquely enhances BRD9876 activity.…
![](https://www.Immune-System-Research.com/"wp-content/uploads"/2020/03/KY-05009-is-an-ATP-Competitive-TNIK-Inhibitor-with-Anti-Tumor-Activity-2020-03-10.jpg)
Multiple myelomas (MM) is a plasma cell malignancy that accounts for approximately 10% of all hematological malignancies. Many new drugs…
![](https://www.Immune-System-Research.com/"wp-content/uploads"/2019/12/CC-92480-is-a-Cereblon-E3-Ubiquitin-Ligase-Modulating-Drug-with-Antimyeloma-Activity-2019-12-10.jpg)
Immunomodulatory agents (IMiDs) are a class of immunomodulatory drugs. Thalidomide analogs have induced significant antimyeloma effects via immune-modulation, antiangiogenesis, and…